Rigel Pharmaceuticals (RIGL) Tops Q2 EPS by 67c; Offers Guidance
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $47.50 --0%
EPS Growth %: -34.9%
Financial Fact:
Income (loss) from operations: -22.74M
Today's EPS Names:
RCBC, GASS, YSG, More
EPS Growth %: -34.9%
Financial Fact:
Income (loss) from operations: -22.74M
Today's EPS Names:
RCBC, GASS, YSG, More
Join SI Premium – FREE
Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q2 EPS of $0.88, $0.67 better than the analyst estimate of $0.21. Revenue for the quarter came in at $78.7 million versus the consensus estimate of $54.94 million.
GUIDANCE:
Rigel Pharmaceuticals sees FY2026 revenue of $285-295 million, versus the consensus of $278.9 million.
For earnings history and earnings-related data on Rigel Pharmaceuticals (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sprinklr (CXM) Tops Q2 EPS by 1c, Offers Guidance
- Palo Alto Networks (PANW) Tops Q4 EPS by 4c, Offers Guidance
- SpaceX (SPCX) PT Raised to $280 at Oppenheimer
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
